UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 28, 2017 (February 28, 2017)
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
| British Columbia, Canada | 001-14956 | 98-0448205 | ||
| (State or other jurisdiction of incorporation) | (Commission file number) | (IRS Employer Identification No.) |
| 2150 St. Elzéar Blvd. West, Laval, Quebec, Canada H7L 4A8 |
| (Address of principal executive offices) (Zip Code) |
(514)744-6792
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On February 28, 2017, Valeant Pharmaceuticals International, Inc. (the “Company”) issued a press release announcing results of operations for the quarter and the year ended December 31, 2016 and certain other financial information as of and for the quarter and the year ended December 31, 2016, as well as providing full year guidance for 2017. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | Description | |
| 99.1 | Press Release of Valeant Pharmaceuticals International, Inc. dated February 28, 2017 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 28, 2017
| VALEANT PHARMACEUTICALS INTERNATIONAL, INC. | ||
| By: | /s/ Paul S. Herendeen | |
| Paul S. Herendeen | ||
| Executive Vice President, Chief Financial Officer | ||
Exhibit Index
Exhibit No. | Description | |
| 99.1 | Press Release of Valeant Pharmaceuticals International, Inc. dated February 28, 2017 | |
